Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma research hub

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

This study looks at new drug Pumitamig with chemotherapy, or Nivolumab with chemotherapy, for advanced stomach, gastroesophageal junction, or oesophageal cancer. It aims to see how safe and effective these combinations are for people who haven't had treatment for their advanced cancer.